ライフサイエンスコーパス: clear cell renal cell carcinoma

1 progression of VHL-associated renal cysts to clear cell renal cell carcinoma.

2 r remains the optimal approach in metastatic clear cell renal cell carcinoma.

3 tor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma.

4 L diseases, including sporadic and inherited clear cell renal cell carcinoma.

5 n an attempt to delay disease progression in clear cell renal cell carcinoma.

6 to improve prediction of recurrence risk in clear cell renal cell carcinoma.

7 eptor inhibitor, in patients with metastatic clear cell renal cell carcinoma.

8 ular network characteristic of conventional (clear) cell renal cell carcinoma.

9 rolled patients with advanced or metastatic, clear-cell, renal cell carcinoma.

10 4 was up-regulated within the vasculature of clear cell-renal cell carcinoma almost 9-fold more than

11 lysis, we assessed 145 patients with primary clear-cell renal-cell carcinoma and defined PBRM1 and BA

12 covered that BAP1 is mutated in about 15% of clear-cell renal-cell carcinoma, and that BAP1 and PBRM1

13 Non-clear cell renal cell carcinomas are histologically and

14 Among patients with locoregional clear-cell renal-cell carcinoma at high risk for tumor r

15 A common genetic mutation found in clear cell renal cell carcinoma (CC-RCC) is the loss of

16 Clear cell renal cell carcinoma (CC-RCC) is the most let

17 carcinomas and eight out of 44 (18%) primary clear cell renal cell carcinomas (CC-RCC) and in one out

18 u tumor suppressor protein are found in most clear cell renal cell carcinomas (CC-RCCs) but not other

19 he genetic hallmark of hemangioblastomas and clear cell-renal cell carcinomas (CC-RCCs) is loss-of-fu

20 ppressor protein pVHL is commonly mutated in clear cell renal cell carcinoma (ccRCC) and has been imp

21 f flux balance analysis in two cancer types, clear cell renal cell carcinoma (ccRCC) and prostate ade

22 tin 3 (TRPM3) channel promotes the growth of clear cell renal cell carcinoma (ccRCC) and stimulates M

23 inically, SCP1 and SCP3 are downregulated in clear cell renal cell carcinoma (ccRCC) and these events

24 scular area mask (VAM) in H&E micrographs of clear cell renal cell carcinoma (ccRCC) cases from The C

25 In agreement, SETD2-mutant clear cell renal cell carcinoma (ccRCC) cells displayed

26 The presence of sarcomatoid features in clear cell renal cell carcinoma (ccRCC) confers a poor p

27 Clear cell renal cell carcinoma (CCRCC) evolves due to m

28 Clear cell renal cell carcinoma (ccRCC) has been previou

29 ysregulation of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncover

30 However, its role in clear cell renal cell carcinoma (ccRCC) has not been des

31 Recent genomic studies of sporadic clear cell renal cell carcinoma (ccRCC) have uncovered n

32 Clear cell renal cell carcinoma (ccRCC) is a gender-bias

33 nd a T cell infiltration score and find that clear cell renal cell carcinoma (ccRCC) is among the hig

34 Clear cell renal cell carcinoma (ccRCC) is an aggressive

35 Clear cell renal cell carcinoma (CCRCC) is an incurable

36 Clear cell renal cell carcinoma (ccRCC) is characterized

37 Clear cell renal cell carcinoma (ccRCC) is characterized

38 Clear cell renal cell carcinoma (CCRCC) is characterized

39 Clear cell renal cell carcinoma (ccRCC) is cytogenetical

40 The long-term prognosis for clear cell renal cell carcinoma (ccRCC) is dramatically

41 Clear cell renal cell carcinoma (ccRCC) is histologicall

42 Clear cell renal cell carcinoma (ccRCC) is the most comm

43 Clear cell renal cell carcinoma (ccRCC) is the most comm

44 Clear cell renal cell carcinoma (ccRCC) is the most comm

45 Clear cell renal cell carcinoma (ccRCC) is the most comm

46 Clear cell renal cell carcinoma (ccRCC) is the most comm

47 Human clear cell renal cell carcinoma (ccRCC) is therapy resis

48 in-depth immune profiling of samples from 73 clear cell renal cell carcinoma (ccRCC) patients and fiv

49 role for dysregulated TGF-beta signaling in clear cell renal cell carcinoma (ccRCC) progression and

50 tion factor (HIF) signaling pathway promotes clear cell renal cell carcinoma (ccRCC) progression and

51 ncer arising from the kidney in adults, with clear cell renal cell carcinoma (ccRCC) representing app

52 iptional profiling of a cohort of 50 primary clear cell renal cell carcinoma (ccRCC) samples from The

53 1) was revealed to be downregulated in human clear cell renal cell carcinoma (ccRCC) samples, which w

54 Recent studies have demonstrated that in clear cell renal cell carcinoma (ccRCC) several chromati

55 On the other hand, clear cell renal cell carcinoma (ccRCC) strongly deviate

56 oit novel compounds with high selectivity to clear cell renal cell carcinoma (ccRCC) with common muta

57 nitinib is a first-line therapy for advanced clear cell renal cell carcinoma (ccRCC), a deadly form o

58 ly targeted therapies have been approved for clear cell renal cell carcinoma (ccRCC), a highly aggres

59 Clear cell renal cell carcinoma (ccRCC), a tubular epith

60 genesis is an important prognostic factor of clear cell renal cell carcinoma (ccRCC), as well as a fa

61 In the most common form of RCC, clear cell renal cell carcinoma (ccRCC), inactivation of

62 Some cancers, such as clear cell renal cell carcinoma (ccRCC), require exogeno

63 Sporadic clear cell renal cell carcinoma (ccRCC), the most common

64 umor suppressor gene (VHL) are a hallmark of clear cell renal cell carcinoma (CCRCC), the most common

65 Clear cell renal cell carcinoma (ccRCC), the most common

66 ted as an early event in almost all cases of clear cell renal cell carcinoma (ccRCC), the most freque

67 For clear cell renal cell carcinoma (ccRCC), three of the fi

68 nderlie the tumorigenesis and progression of clear cell renal cell carcinoma (ccRCC), we studied the

69 ints-average sensitivity and specificity for clear cell renal cell carcinoma (ccRCC)-were compared be

70 six tandem BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

71 rface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

72 otein expression, and methylation changes in clear cell renal cell carcinoma (ccRCC).

73 on, multiple renal cysts, and early onset of clear cell renal cell carcinoma (ccRCC).

74 central nervous system hemangioblastoma and clear cell renal cell carcinoma (CCRCC).

75 d of care for first-line therapy of advanced clear cell renal cell carcinoma (ccRCC).

76 ed as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC).

77 major hurdle in improving the management of clear cell renal cell carcinoma (ccRCC).

78 odeler, is implicated in the pathogenesis of clear cell renal cell carcinoma (ccRCC).

79 genomic ITH has previously been reported in clear cell renal cell carcinoma (ccRCC).

80 outcomes for African American patients with clear cell renal cell carcinoma (ccRCC).

81 dau (VHL) gene mutations are associated with clear cell renal cell carcinoma (ccRCC).

82 ection of miR-204 and miR-210 related to the clear cell Renal Cell Carcinoma (ccRCC).

83 s a direct transcriptional target of HIFs in clear cell renal cell carcinoma (ccRCC).

84 eases, including both sporadic and inherited clear cell renal cell carcinoma (ccRCC).

85 mor suppressor VHL, the most common event in clear cell renal cell carcinoma (ccRCC).

86 rimethyltransferase, have been identified in clear cell renal cell carcinoma (ccRCC); however it is u

87 C is frequently inactivated in patients with clear cell renal cell carcinoma (ccRCC); however, it is

88 ancer subtypes from The Cancer Genome Atlas: clear cell renal cell carcinoma (ccRCC, also known as ki

89 More than 90% of clear cell renal cell carcinomas (ccRCC) exhibit inactiv

90 essor gene is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ab

91 VHL-deficient clear cell renal cell carcinomas (ccRCC), the most commo

92 tumor-suppressor gene (VHL) is lost in most clear cell renal cell carcinomas (ccRCC).

93 d to the hereditary VHL disease and sporadic clear cell renal cell carcinomas (CCRCC).

94 VEGF, which drives abnormal angiogenesis in clear cell renal cell carcinomas (ccRCC).

95 r suppressor gene in hereditary and sporadic clear-cell renal cell carcinoma (ccRCC) have led to new

96 Clear-cell renal cell carcinoma (ccRCC) is a common aggr

97 Importantly, clear-cell renal cell carcinoma (ccRCC) is frequently as

98 Surgery for clear-cell renal cell carcinoma (ccRCC) might benefit fr

99 n and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models.

100 von Hippel-Lindau (VHL) are major causes of clear-cell renal cell carcinoma (ccRCC) that may origina

101 In clear-cell renal cell carcinoma (ccRCC), inactivation of

102 or the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC).

103 ad to benign and malignant tumors, including clear-cell renal cell carcinoma (ccRCC).

104 Clear cell renal cell carcinomas (ccRCCs) are characteri

105 Clear cell renal cell carcinomas (ccRCCs) display diverg

106 A subset of familial and sporadic clear cell renal cell carcinomas (ccRCCs) is believed to

107 suppressor is inactivated in the majority of clear cell renal cell carcinomas (ccRCCs), leading to in

108 pVHL-defective clear cell renal cell carcinoma cell lines display unexp

109 Intriguingly, clear cell renal cell carcinoma cells (ccRCC) have a dys

110 ulation by the transcription factor HNF4A in clear cell renal cell carcinoma, despite no differential

111 Clear-cell renal-cell carcinomas display divergent clini

112 Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification o

113 rchival specimens of primary organ-confined, clear-cell, renal cell carcinoma from patients who had u

114 he other subtypes of kidney neoplasms (e.g., clear-cell renal cell carcinoma) harbored PIK3CA mutatio

115 iology of renal cell carcinoma, particularly clear cell renal cell carcinoma, have led to the develop

116 glioma multiforme, breast, colorectal, skin, clear cell renal cell carcinoma, hepatic and prostate ca

117 els of primary and metastatic pVHL-defective clear cell renal cell carcinoma in an on-target fashion.

118 ur recurrence after nephrectomy in localised clear cell renal cell carcinoma is well characterised by

119 Clear-cell renal cell carcinoma is a frequent cause of d

120 Clear cell renal cell carcinoma masses are more likely t

121 years and older with advanced or metastatic clear-cell renal cell carcinoma, measurable disease, and

122 mors that included renal oncocytomas and non-clear cell renal cell carcinomas (nccRCCs), consisting o

123 gle-agent targeted therapies in advanced non-clear cell renal cell carcinoma (ncRCC) compared with cl

124 ll carcinoma and renal oncocytoma but not by clear cell renal cell carcinoma or by papillary renal ce

125 linical outcome in patients with stage I-III clear cell renal cell carcinoma, providing a more accura

126 in zebrafish and murine xenograft models of clear cell renal cell carcinoma (RCC) and pancreatic ade

127 iews the evolution of targeted therapies for clear cell renal cell carcinoma (RCC) and recent develop

128 Clear cell renal cell carcinoma (RCC) is considered an i

129 Clear cell renal cell carcinoma (RCC) is the most common

130 l renal cell carcinoma (ncRCC) compared with clear cell renal cell carcinoma (RCC) supports the study

131 a pathway is well-known to be deregulated in clear cell renal cell carcinoma (RCC) whereas in papilla

132 e has a critical role in the pathogenesis of clear cell renal cell carcinoma (RCC), because VHL mutat

133 unction occurs in familial and most sporadic clear cell renal cell carcinoma (RCC), resulting in the

134 tionship between tumor size and perfusion in clear cell renal cell carcinoma (RCC).

135 ll as the majority of patients with sporadic clear cell renal cell carcinoma (RCC).

136 significant clinical activity in metastatic clear cell renal cell carcinoma (RCC).

137 (VHL) is an early event in >60% of sporadic clear cell renal cell carcinoma (RCC).

138 e revolutionized the treatment of metastatic clear cell renal cell carcinoma (RCC).

139 m patients before undergoing nephrectomy for clear cell renal cell carcinoma (RCC; n = 48), normal vo

140 Clear cell renal cell carcinomas (RCC) frequently displa

141 In all, 39 clear cell renal cell carcinomas (RCC), seven primary an

142 Clear cell renal cell carcinomas (RCC), the major histol

143 75 genes were analyzed in four conventional (clear cell) renal cell carcinomas (RCC), one chromophobe

144 r endothelial growth factor in the growth of clear-cell renal cell carcinoma (RCC) has identified a p

145 ) has a critical role in the pathogenesis of clear-cell renal cell carcinoma (RCC), as VHL mutations

146 nactivation of the von Hippel-Lindau gene in clear-cell renal cell carcinomas (RCC) leads to overexpr

147 r suppressor pVHL is lost in the majority of clear-cell renal cell carcinomas (RCC).

148 signaling and was highly expressed in 99% of clear cell renal cell carcinomas (RCCs), the most preval

149 0 cm) included in this study, 108 (55%) were clear cell renal cell carcinomas (RCCs); 30 (15%), papil

150 viously untreated metastatic or unresectable clear-cell renal-cell carcinoma received oral regorafeni

151 sphorylated STAT3 are remarkably elevated in clear-cell renal-cell carcinoma relative to adjacent nor

152 mmune infiltrates in lung adenocarcinoma and clear cell renal cell carcinoma, respectively.

153 roarray samples from tumors of patients with clear cell renal cell carcinoma shows that increased CDC

154 In patients with metastatic non-clear cell renal cell carcinoma, sunitinib improved prog

155 tute a significant portion of aggressive non-clear cell renal cell carcinomas that have no standard t

156 is for a molecular genetic classification of clear-cell renal-cell carcinoma that could influence tre

157 Clear cell renal cell carcinoma, the most common form of

158 ed 615 patients with locoregional, high-risk clear-cell renal-cell carcinoma to receive either suniti

159 with treatment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between Se

160 A total of 361 patients with metastatic clear cell renal cell carcinoma were randomly assigned e

161 med metastatic or locally advanced (or both) clear-cell renal cell carcinoma were randomly assigned (

162 pression predisposes to hemangioblastoma and clear cell renal cell carcinoma, whereas specific point

163 pe of how cancer is treated, particularly in clear cell renal cell carcinoma, which is molecularly li

164 of 626 patients from France with stage I-III clear cell renal cell carcinoma who had also undergone n

165 cal outcome in 942 patients with stage I-III clear cell renal cell carcinoma who had undergone a neph

166 papillary, chromophobe, or unclassified non-clear cell renal cell carcinoma with no history of previ

167 ndings identify mutation-defined subtypes of clear-cell renal-cell carcinoma with distinct clinical o